Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Oct;4(19):386.
doi: 10.21037/atm.2016.08.26.

Is stronger better in curing hepatitis C virus infection?

Stanislas Pol  1
Affiliations
Comment

Is stronger better in curing hepatitis C virus infection?

Stanislas Pol. Ann Transl Med. 2016 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. S Pol has received consulting and lecturing fees from Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Gilead, MSD, Novartis, Abbvie and grants from Bristol-Myers Squibb, Gilead, Roche and MSD.

Comment on

References

    1. Bourlière M, Khaloun A, Wartelle-Bladou C, et al. Future treatment of patients with HCV cirrhosis. Liver Int 2012;32 Suppl 1:113-9. 10.1111/j.1478-3231.2011.02702.x - DOI - PubMed
    1. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100. 10.1038/nature08960 - DOI - PMC - PubMed
    1. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012;56:5387-96. 10.1128/AAC.01186-12 - DOI - PMC - PubMed
    1. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-8. 10.1002/hep.24724 - DOI - PubMed
    1. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-62. 10.1016/j.jhep.2012.09.037 - DOI - PubMed

LinkOut - more resources